Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Sivelestat) VI
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS)
are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the
prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with
sivelestat may be beneficial. This study was designed to test the hypothesis that the
administration of sivelestat during the acute phase of AAS will result in a reduced incidence
of SIRS and MODS.